Paul Hudson (Getty Images)

Sanofi, Glax­o­SmithK­line jump back in­to the PhI­II race for a Covid vac­cine — as the win­ners con­gre­gate be­hind the fin­ish line

Sanofi got out ear­ly in the race to de­vel­op a vac­cine us­ing more of a tra­di­tion­al ap­proach, then de­railed late last year as their can­di­date failed to work in old­er peo­ple. Now, af­ter like­ly miss­ing the bus for the bulk of the world’s af­flu­ent na­tions, they’re back from that em­bar­rass­ing col­lapse with a sec­ond at­tempt us­ing GSK’s ad­ju­vant that may get them back on track — with a po­ten­tial Q4 launch that the rest of the world will be pay­ing close at­ten­tion to.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA